An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

Clicks: 367
ID: 269778
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #10 of 14 articles by views in the american journal of gastroenterology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The use of interferon- and RBV-free regimens for HCV is associated with better patients' experience and work productivity during treatment.
Reference Key
zm2016thean Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Younossi ZM;Stepanova M;Henry L;Nader F;Hunt S;;
Journal the american journal of gastroenterology
Year 2016
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/27021197
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine female male middle aged Clinical Trial Phase III Multicenter Study Retrospective Studies drug therapy combination antiviral agents / therapeutic use* ribavirin / therapeutic use chronic / drug therapy* sofosbuvir / therapeutic use maria stepanova zobair m younossi interferons / therapeutic use patient reported outcome measures* pmid:27021197 doi:10.1038/ajg.2016.99 sharon hunt benzimidazoles / therapeutic use fluorenes / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.